Growth Hormone Deficiency Companies

Latest growth hormone deficiency Companies Update

• 
  

  June 2023: The therapy for growth hormone insufficiency in children, developed by Pfizer Inc and OPKO Health Inc, has been granted approval by the U.S. Food and Drug Administration. The clearance, after to an earlier rejection by the FDA in January of the previous year, resulted in a little increase in Pfizer's shares and a roughly 19% rise in Opko Health's shares during premarket trading. The approval has been granted for the administration of a hormone therapy, which may be administered through injection. This medication, marketed under the brand name Ngenla, has been authorized for the purpose of treating pediatric patients who are three years of age or older. It is anticipated that Ngenla will be made accessible in the United States by August. For an extended period, the administration of daily injections of growth hormones has been considered the prevailing approach in medical practice.

  
  

• September 2023: Ascendis Pharma A/S disclosed the findings of the enliGHten trial, an open-label extension study conducted to assess the enduring safety and effectiveness of TransCon hGH as a weekly therapeutic regimen for pediatric and adolescent patients diagnosed with growth hormone deficit (GHD). The enliGHten trial had a total of 298 individuals, with an average age of 10.3 years. The participants in these clinical studies were administered TransCon hGH for a maximum duration of 6 years. Furthermore, the findings of this study provide evidence that the achievement of long-term treatment objectives can be effectively and securely accomplished with the administration of TransCon hGH on a weekly basis.

• Anhui Anke Biotechnology (Group) Co. Ltd.


• Pfizer Inc.


• Genetech Inc.


• Biopartners GmbH


• Lifetech Labs


• Zhongshan Hygene Biopharm Co. Ltd.


• Novo Nordisk A/S


• Eli Lily and Company


• Ipsen S.A.